Pfizer's stock rose 0.48% in its latest trading session, outperforming the S&P 500's 0.13% uptick, while other indices ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

Eli Lilly’s latest innovation, orforglipron, has emerged as a formidable contender in the weight-loss medication arena. The pill has demonstrated comparable results to Ozempic, a leading injectable ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

The stock's fall snapped a three-day winning streak.

Pfizer just pulled the plug on its oral weight-loss pill danuglipron after a liver injury case raised safety alarms. This decision underscores how the path from lab to medicine cabinet is riddled with ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...

Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...